Treatment Algorithm: This is the algorithm we’ve used during our 🗣️ w/ joaquim bellmunt for #BladderCancer! This includes #NIAGARA, though we’re still awaiting FDA Oncology approval. #OncTwitter #MedTwitter CancerNetwork®

Metabolic engineering to facilitate anti-tumor immunity dlvr.it/TJTtYM

Spontaneous regression of metastatic clear cell #RenalCellCarcinoma: A report of a rare case and a review of the literature. Spontaneous regression in #ccRCC remains a rare but intriguing phenomenon! A new case suggests that tumor biopsies and antibiotic use may trigger immune

The FDA approved perioperative duvalumab with neoadjuvant chemo for muscle invasive bladder cancer today. It’s the only perioperative immune therapy trial with significant OS (0.75). Surgical safety was maintained. NCCN approval recently too #GUtrends25 fda.gov/drugs/resource…

Moving into the castration-sensitive setting. Presentation by Michael Morris, MD Memorial Sloan Kettering Cancer Center. Written coverage by Zach Klaassen Georgia Cancer Center bit.ly/3Rr14Nu Prostate Cancer Foundation PSMA & Beyond Conference #PSMAandBeyond2025

PSMA PET is a big step forward—but it’s not the full answer. ✅ Detects csPCa (82% sensitivity) ✅ Boosts accuracy with MRI (up to 91%) 🚫 NPV too low to skip biopsy—not yet 🚫 Can’t replace LND in staging—not yet Use it wisely. Combine, don’t over-rely. #ProstateCancer #PSMAPET

ADT remodels the tumor microenvironment from immunologically cold to hot. Matthew Dallos, MD Memorial Sloan Kettering Cancer Center joins Andrea Miyahira Prostate Cancer Foundation in this discussion of how androgen deprivation therapy reshapes the immune landscape in localized #ProstateCancer. #WatchNow >

International perspectives on the GU Oncology Early Thought Leaders conference. Regina Barragan-Carrillo Instituto Nacional de Cancerología joins Zach Klaassen Georgia Cancer Center to discuss her experience and share how the conference gave space to soft skills, honest stories, and real connection. A powerful reminder

🩻🧬 Integrating molecular imaging with genetic profiling holds the potential to enhance survival outcomes in patients with prostate cancer. Don’t miss it! 🔜 #ASCO25 Nora Osvaldo Garcia anna scavuzzo Diego Lopez Oncologist

A simple move, a big impact: Giving IV magnesium before cisplatin cut kidney injury risk by 20%! Safe. Cheap. Available. JAMA Oncology OncoAlert Oncology Brothers LARVOL jamanetwork.com/journals/jamao…

One page takeaway from #NIAGARA study that resulted in #durvalumab’s FDA Oncology approval on March 28, 2025 for resectable muscle invasive #BladderCancer #OncTwitter #MedTwitter #gusm OncoAlert Tom Powles

⚡️ On European Urology - European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2025 Guidelines #BladderCancer europeanurology.com/article/S0302-…

⚡️ Global trends in the epidemiology of bladder cancer: challenges for public health and clinical practice #BladderCancer NatureRevClinOncol nature.com/articles/s4157…

Breaking news ASCO #ASCO25 👉 1st biomarker selected, positive ph3 trial in mHSPC #ProstateCancer 👉Abiraterone+ niraparib/PARPi significant improve rPFS (favorable OS trend) in HRR+ pts (⬆️benefit in BRCApts), NGS testing must inall AttardLab PCF Science UroToday.com OncoAlert

🚨 NEW in #EuropeanUrology By Saum Ghodoussipour Roger Li Sarah P. Psutka MD MS Trinity J. Bivalacqua Joan Palou Redorta et al Can novel intravesical therapies change the game for non–muscle-invasive bladder cancer? This systematic review explores: ✅ BCG-based combos ✅ Gene & immune therapies ✅ Innovative drug

Breaking News from ph3 Embark trial👉Enzalutamide+ADT improve overall survival (OS) vs. ADT alone in Non-Metastatic HSPC #Prostatecancer Congrats to Stephen Freedland, MD neal shore & team! Earlier enza works better! Link👉 rb.gy/iyc3f2 OncoAlert UroToday.com Prostate Cancer Foundation

Sequencing with RLT in #mCRPC. Presentation by Tanya Dorff City of Hope addressing treatment sequencing in advanced #ProstateCancer. She notes PARP inhibitors show superior efficacy when used early in BRCA2-altered patients. #WatchNow > bit.ly/4jOQY50 PSMA & Beyond Conference

🔥 What’s the hottest topic in oncology right now? CANCER + THE MICROBIOME. We reviewed the current evidence on how manipulating the gut microbiome can enhance immunotherapy, and what’s next. Led by @MontyPal with insights from Zeynep Zengin and me. 📍Read here:

🚨 Potential Practice Changer in #BladderCancer 🚨 KEYNOTE-905 (EV-303) – cisplatin-ineligible MIBC Peri-op pembrolizumab + enfortumab vedotin vs surgery alone: ✅ ↑ Event-Free Survival ✅ ↑ Overall Survival ✅ ↑ Pathologic CR rates 📌 First Phase 3 to show survival benefit

🚨 IMvigor011 Press Release High-risk MIBC, post-cystectomy 👉 ctDNA+ → Atezolizumab improved DFS & OS vs placebo ❌ IMvigor010 (Atezo, all-comers) = negative ✅ CheckMate-274 (Nivo, all-comers) = DFS benefit → SOC ✅ IMvigor011 (Atezo, ctDNA+) = precision win ➡️ From “treat